14 Mar 2013 Calon wins TSB Biomedical Catalyst Award

Calon is delighted to announce that it has been awarded a c£1.7m grant by the Technology Strategy Board to assist with the development of its novel MiniVAD ventricular assist device. A major part of this work is to develop a series of innovative assays to assess the damage caused by mechanical circulatory support pumps to key blood constituents and to total blood function.

In conjunction with collaborators –The Thrombosis Research Institute (London) and the Institute of Life Science (Swansea University) – the grant will lead to the creation of several new techniques.
These will enable blood pump engineers to better understand the impact of device design on the individual components of blood that have been demonstrated to play a role in the frequent coagulation and bleeding dysfunction observed in current VAD patients. This enhanced insight will directly inform the design of the Calon MiniVAD leading to a pump with substantially improved biocompatibility.

Commenting on this award, Calon CTO Dr Graham Foster said ‘We are delighted that the TSB has supported this important work to enable the design of the MiniVAD to be underpinned by excellent science which we hope will result in a pump with dramatically reduced rates of hospital readmission arising from adverse blood related complications. We firmly believe that understanding blood function effects is the key to designing a better VAD and we are delighted that TSB and our collaborators share this perspective’.

For more information contact Graham Foster, Chief Technology Officer, on +44 (0)1792 602811



Disclaimer: Calon Cardio’s VAD devices are not available for sale, including in the United States of America